Filana Therapeutics, Inc. Excess Tax Benefit from Share-based Compensation, Financing Activities
Filana Therapeutics, Inc. (FLNA) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $57.00 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2015-02-18.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2015-02-18
- Filana Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2012 was $57.00K.
- Filana Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2011 was -$339.00K, a 216.90% decline from fiscal 2010.
- Filana Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2010 was $290.00K.
- Filana Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2009 was -$9.00K.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|
| 2012-12-31 | $57.00K 10-K · filed 2015-02-18 |
| 2011-12-31 | -$339.00K 10-K · filed 2014-02-05 |
| 2010-12-31 | $290.00K 10-K · filed 2013-02-08 |
| 2009-12-31 | -$9.00K 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |